Top

Archives of Gynecology and Obstetrics

Published in:

01-10-2011 | Reproductive Medicine

Schizophrenia and Stein–Leventhal syndrome: comorbidity features

Author: Naira R. Matevosyan

Published in: Archives of Gynecology and Obstetrics | Issue 4/2011

Abstract

Objective

To explore shared pathogenesis between schizophrenia and polycistic ovary syndrome (PCOS).

Methods

Ninety-six studies of schizophrenia and PCOS from a mean sample of 139 women are recruited from PubMed and FASTSTATS for geometrical regression analysis. Parametric and observational properties of both diseases (gene polymorphism, monoamines, gonadal steroids, gonadotropins, thyroid hormones, insulin sensitivity index, hirsute index, oligomenorrhea, anhedonia, asociality, apathy, emotional withdrawal, alogia, poor rapport, stereotypical thinking, hyperkinetic reactions, treatment with valproate) are stochastically distributed in the elliptical area.

Results

Results of both analyses suggest that insulin resistance and elevated testosterone are predictive to comorbidity. These associations are stronger with calculation from elliptical model (r ² = 0.92) than a traditional regression analysis (r ² = 0.65).

Conclusions

Insulin resistance and elevated testosterone in women contribute in shared pathogenesis of schizophrenia and PCOS. 3D regression analysis shows greater strength of association with the “criterion” value.

Agarwal SK, Judd HL, Magoffin DA (1996) A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 81:3686–3691PubMedCrossRef

Arad M, Weiner I (2010) Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis. Neuropsychopharmacology 35(7):1570–1582PubMedCrossRef

Barnes RB (1998) The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies. J Endocrinol Invest 21(9):576–579

Bassett AS, Hodgkinson K, Chow RWC et al (1998) 22q11 deletion syndrome in adults with schizophrenia. Am J of Med Genet Part B: Neuropsychiatr Genet 81(4):328–337CrossRef

Baumgartner A, Gräf KJ, Kürten I et al (1988) The hypothalamic-pituitary-thyroid axis in psychiatric patients and healthy subjects. Repeated measurements of thyroxine, free thyroxine, triiodothyronine, free triiodothyronine, and reverse triiodothyronine in patients with major depressive disorder, schizophrenia and healthy subjects. Psychiatry Res 24(3):283–305CrossRef

Beard AW (1965) Experiences of schizophrenia. Br Med J 1:848–849CrossRef

Bodén R, Haenni A, Lindström L, Sundström J (2009) Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res 115(203):141–145PubMedCrossRef

Bowden CL, Singh V (2008) Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand 111(s426):13–20CrossRef

Brody EB, Man EB (1950) Thyroid function measured by serum precipitable iodine determinations in schizophrenic patients. The Am J of Psychiatr 107:357–359

10.

Bruce-Jones W, Zolese G, White P (1993) Polycystic ovary syndrome and psychiatric morbidity. J Psychosom Obstet Gynecol 14(2):111–116CrossRef

11.

Canuso CM, Goldstein JM, Wojcik J et al (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatr Res 111(1):11–20CrossRef

12.

Campbell M, Fish B, David R et al (2005) Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Dev Disord 2(4):343–358CrossRef

13.

Carney CP, Jones L, Woolson RF (2007) Medical comorbidity in women and men with schizophrenia. J Gen Intern Med 21(11):1133–1137CrossRef

14.

Chua WL- LC, de Santiago AI, Kulkarni J, et al. Estrogens for schizophrenia. Cochrane Database of Systematic Reviews, 2010; Issue 1

15.

Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane Database Systematic Reviews, 2005; (4):CD004719

16.

Chun-Sen H, Chien-Hua W, Wan-Chun C et al (2010) Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 27(5):300–306PubMedCrossRef

17.

Ciotta L, De Leo V, Galvani F et al (1999) Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. Hum Reprod 14(12):2951–2958PubMedCrossRef

18.

Cohen RZ, Seeman MV, Gotowiec A et al (1999) Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatr 156:1059–1065PubMed

19.

Cooper NJ, Jones DR, Sutton AJ (2005) The use of systematic reviews when designing studies. Clin Trials 2:260–264PubMedCrossRef

20.

Cope SL (1965) Hormone reviews. Br Med J 1:849CrossRef

21.

Correll C, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Child Adolesc Psychiatr 45(7):771–791CrossRef

22.

Dasgupta A, Singh OP, Rout JK et al (2010) Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatr 34(7):1202–1207CrossRef

23.

DeLisi LE, Smith AB, Razi K et al (2000) Investigation of a candidate gene for schizophrenia on Xq13 previously associated with mental retardation and hypothyroidism. Am J Med Genet 96(3):398–403PubMedCrossRef

24.

Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18(6):774–800PubMedCrossRef

25.

Eaton WW, Byrne M, Ewald H et al (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish National Registers. Am J Psychiatr 163:521–528PubMedCrossRef

26.

Eldar-Geval T, Shoham M, Rösler A et al (2007) Subclinical hypothyroidism in infertile women: the importance of continuous monitoring and the role of the thyrotropin-releasing hormone stimulation test. Gynecol Endocrinol 23(6):332–337CrossRef

27.

Elsenbruch S, Hahn S, Kowalsky D et al (2008) Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:5801–5807CrossRef

28.

Ernst CL, Goldberg JF (2002) The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatr 63(Suppl4):42–55

29.

Farrell K, Antoni MH (2010) Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: bio-behavioral mechanisms and interventions. Fertil Steril 94(5):1565–1574PubMedCrossRef

30.

Feldman D, Goldberg JF (2002) A preliminary study of the relationship between Clozapine-induced weight gain and menstrual irregularities in schizophrenic, schizoaffective, and bipolar women. Ann Clin Psychiatr Clin Psychol-Adult 14(1):17–21

31.

Fisun A (2010) Female-specific health problems in mental patients. Curr Opin Psychiatr 23(4):378–382CrossRef

32.

Fitko R, Jan Kucharski J, Szlezyngier B (1995) The importance of thyroid hormone in experimental ovarian cyst formation in gilts. Animal Reprod Sci 39(2):159–168CrossRef

33.

de França Neto AH, Rogatto S, Do Amorim MM et al (2010) Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol 26(10):708–711PubMedCrossRef

34.

Freeman R, Pollack R, Rosenbloom E (2010) Assessing impaired glucose tolerance and insulin resistance in Polycystic Ovarian Syndrome with a muffin test: alternative to glucose tolerance test. Endocr Pract 3:1–24

35.

Gerli S, Papaleo E, Ferrari A, Di Renzo GC (2007) Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 11:347–354PubMed

36.

Ghaziuddin M (1988) Polycystic ovary disease, manic-depressive illness and mental retardation. J Intellect Disabil Res 33(4):335–338CrossRef

37.

Ghosh S, Kabir SN, Pakrashi A, et al (1993) Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res Pediatr 39(1–2):61–66

38.

González A, Sáez ME, Aragón MJ et al (2006) Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome. Hum Reprod 21(4):943–951PubMedCrossRef

39.

Goodarzi MO (2007) The Polycystic ovary syndrome: current concepts on pathogenesis and clinical care. B chapter Endocr Updates 27:29–42CrossRef

40.

Grigoriadis S, Seeman MV (2002) The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatr 47:437–442

41.

Haddad PM, Das A, Ashfaq M, Wieck A (2009) A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 5(5):539–551PubMedCrossRef

42.

Hanzu FA, Radian S, Attaoua R et al (2010) Association of insulin receptor genetic variants with polycystic ovary syndrome in a population of women from Central Europe. Fertil Steril 94(6):2389–2392

43.

Hendrick V, Altshuler LL, Burt VK (1996) Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 4(4):200–2007PubMedCrossRef

44.

Herken H, Erdal M, Aydin N et al (2009) The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 28(10):515–519PubMedCrossRef

45.

Hirschhorn JN, Lohmueller KB, Kirk Byrne E et al (2002) A comprehensive review of genetic association studies. Genet Med 4(2):45–61PubMedCrossRef

46.

Hoff AL, Kremen WS, Wieneke MH et al (2001) Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 158:1134–1139PubMedCrossRef

47.

Hoffer A (2001) Thyroid and Schizophrenia. J Orthomol Med 16(4):205–212

48.

Huang MC, Lu ML, Tsai CJ et al (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120(4):274–280PubMedCrossRef

49.

Indhavivadhana S, Wongwananuruk T, Rattanachaiyanont M et al (2010) Prevalence of metabolic syndrome in reproductive-aged polycystic ovary syndrome Thai women. J Med Assoc Thail 93(6):653–660

50.

Janssen OE, Mehlmauer N, Hahn S et al (2004) High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 150(3):363–369PubMedCrossRef

51.

Johnstone EC, Owens DG, Crow TJ et al (1986) Hypothyroidism as a correlate of lateral ventricular enlargement in manic-depressive and neurotic illness. British J Psychiatry 148:317–321CrossRef

52.

Joffe H, Cohen LS, Suppesb T et al (2006) Longitudinal follow-up of reproductive and metabolic features of Valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 60(12):1378–1381PubMedCrossRef

53.

Joffe H, Hall JE, Cohen LS et al (2003) A putative relationship between Valproic Acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 11(2):99–108PubMedCrossRef

54.

Joffe H, Hayes FJ (2008) Menstrual cycle dysfunction associated with neurological and psychiatric disorders. Their treatment in adolescents. Ann N Y Acad Sci 1135:219–229 (Issue The Menstrual Cycle and Adolescents)PubMedCrossRef

55.

Kelly DL, Conley RR (2005) Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 66(1):80–84PubMedCrossRef

56.

Ko YH, Joe SH, Cho W et al (2006) Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53(4):169–175PubMedCrossRef

57.

Kopala LC, Lewine R, Good KP et al (1997) Clinical features of schizophrenia in a woman with hyperandrogenism. J Psychiatry Neurosci 22(1):56–60PubMed

58.

Koponen HJ, Hakko HH, Saari KM et al (2010) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J biol Psychiatry 11(2Pt2):262–267PubMedCrossRef

59.

Kulkarni J (2009) Oestrogen–a new treatment approach for schizophrenia? Med J Aust 190(4 Suppl):S37–38PubMed

60.

Kulkarni J (2010) Special issues in managing long-term mental illness in women. Int Rev Psychiatry 22(2):183–190PubMedCrossRef

61.

Kulkarni J, Riedel A, de Castella AR et al (2010) Estrogen—a potential treatment for schizophrenia. Schizophr Res 48(1):137–144CrossRef

62.

Strauss LegroRS, III JF (2001) Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78(3):569–576

63.

Lindley SE, Schröder CM, O`Hara R.(2008) Insulin resistance syndrome and neuropsychiatric disease Informa pp. 49-53

64.

Mackin P, Ruttledge S. Physical comorbidity in bipolar disorder. Med Psychiatr Ser 2007/35; pp 391-394

65.

Mantel N (1963) Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58(303):690–691

66.

Martinos A, Rinieris P, Souvatzoglou A et al (1986) Effects of six weeks’ neuroleptic treatment on the pituitary-thyroid axis in schizophrenic patients. Biol Psychiatry 16:2–3

67.

Matsunaga H, Sarai M (1993) Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Psychiatry Clin Neurosci 47(4):825–842CrossRef

68.

Nestler JE, Jakubowicz DJ (1997) Lean women with PCOS respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 82(12):4075–4079PubMedCrossRef

69.

Normand ST, Jou KH (2002) Sample size considerations in observational health care quality studies. Stat Med 21:331–345PubMedCrossRef

70.

Oud MJ, Meyboom-de Jong B (2009) Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 9(10):32CrossRef

71.

Padmavati R (2010) Metabolic syndrome in mental disorders. Indian J Med Res 131:11–13PubMed

72.

Pantasri T, Vutyavanich T, Sreshthaputra O et al (2010) Metabolic syndrome and insulin resistance in Thai women with polycystic ovary syndrome. J Med Assoc Thail 93(4):406–412

73.

Pethö B, Karczag I, Czeizel A (1982) Familially accumulated schizophrenia (folie à cinq) in association with Stein–Leventhal syndrome. Psychiatria Clinica (Basel) 15(4):206–211

74.

Pethö B, Karczag I, Czeizel E (1981) Stein-Leventhal syndrome associated with cumulative familial schizophrenia (folie à cinq). Orv Hetil 122(48):2965–2966PubMed

75.

Philibert RA, Sandhu HK, Hutton AM et al (2001) Population-based association analyses of the HOPA ^12bp polymorphism for schizophrenia and hypothyroidism. Am J Med Genet Part B Neuropsychiatr Genet 105(1):130–134CrossRef

76.

Prentice R (1976) Use of the logistic model in retrospective studies. Biometrics 32(3):599–606PubMedCrossRef

77.

Rao ML, Kölsch H (2003) Effects of estrogen on brain development and neuroprotection–implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28(Suppl 2):83–96PubMedCrossRef

78.

Rasgon NL.(2001) Investigating polycystic ovary syndrome in women with bipolar disorder. Psychiatr Times 18(5)

79.

de Resende LO, dos Reis RM, Ferriani RA et al (2010) Concentration of steroid hormones in the follicular fluid of mature and immature ovarian follicles of patients with polycystic ovary syndrome submitted to in vitro fertilization. Ravista Brasileira de Gynecologia e Obstetr 32(9):447–453CrossRef

80.

Rheingold JC (1939) Autonomic integration in schizophrenia. Autonomic status determined statistically, the thyroid factor, and a possible thyroid-hypothalamus mechanism. Psychosom Med 1:397–413

81.

Riecher-Rössler A.(2005) Estrogens and schizophrenia. Estrogen Effects in Psychiatric Disorders, pp. 31-52

82.

Riecher-Rössler A, Häfner H, Stumbaum M et al (1994) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20(1):203–214PubMed

83.

Roepke S, Ziegenhorn A, Kronsbein J et al (2010) Incidence of polycystic ovaries and androgen serum levels in women with borderline personality disorder. J Psychiatr Res 44(13):847–852PubMedCrossRef

84.

Ryan WG, Roddam RF, Grizzle WE (1994) Thyroid function screening in newly admitted psychiatric inpatients. Ann Clin Psychiatry 6(1):7–12PubMedCrossRef

85.

Sandhu HK, Sarkar M, Turner BM et al (2003) Polymorphism analysis of HOPA: a candidate gene for schizophrenia. Am J Med Genet 123B(1):33–38PubMedCrossRef

86.

Seeman MV, Lang M (1990) The role of estrogens in schizophrenia gender differences. Schizophr Bull 16(2):185–194PubMed

87.

Shikaeva FV, Efimenko NF (1994) Hormonal-mediator interrelationships in polycystic ovary syndrome. Problemi Endocrinologii 40(4):33–35

88.

Simson GM, Cranswick EH, Blair ChB (1963) Thyroid indeces in chronic schizophrenia. Nerv Ment Dis 137(6):582–590CrossRef

89.

Smirnova LK, Zorenko TI ((1993)) Thyroid functional activity in schizophrenic patients with aggressive sexual behavior. Zhurnal Nevrologi I Psikhiatrii Imeni S. S. Korsakova 93(4):68–70

90.

Sonino N, Peruzzi P (2009) A psychoneuroendocrinology service. Psychother Psychosom 78(6):346–351PubMedCrossRef

91.

Sridhar GR, Nagamani G (1993) Hypothyroidism presenting with polycystic ovary syndrome. J Assoc Physicians-India 41(2):88–90PubMed

92.

Steiner J, Walter M, Guest P et al (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15(1):3–4PubMedCrossRef

93.

Sundararaman PG, Shweta, Sridhar GR (2008) Psychosocial aspects of women with polycystic ovary syndrome from South India. J Assoc Physicians India 56: 945–948

94.

Sutton AJ, Abrams KR, Lambert PC, et al. Meta-analysis in practice: a critical review of available software. Biostatistics; In: Meta-Analysis in Medicine and Health Policy, 2000. New York, Marcel Dekker

95.

Takeuchi T, Tsutsumi O, Taketani Y (2008) Abnormal response of insulin to glucose loading and assessment of insulin resistance in non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol 24(7):385–391PubMedCrossRef

96.

Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8(1):41PubMedCrossRef

97.

Verma SK, Subramaniam M, Liew A, Poon LY (2009) Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 70(7):997–1000PubMedCrossRef

98.

Vicennati V, Gambineri A, Calzoni F et al (1998) Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47(8):988–992PubMedCrossRef

99.

Vuguin PM (2010) Interventional studies for polycystic ovarian syndrome in children and adolescents. Pediatr Health 4(1):59–73CrossRef

100.

Wagner KD, Kowatch RA.(2001) Child and adolescent bipolar disorder: focus on differential diagnosis and management. A Monograph of Continuing Medical Education Credit, IL

101.

Weber NS, Cowan DN, Millikan AM, Niebuhr DW (2009) Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv 60(8):1059–1067PubMedCrossRef

102.

West GR (1986) A stochastic analysis of an input-output model. Econometrica 54(2):363–374CrossRef

103.

Wheeler CJ, Keye WR, Peterson CM. (2010) Polycystic ovary syndrome. Reproductive Endocrinology and Infertility, Part 2, pp 147-182

104.

Wilk AI, Jensen NM, Havighurst TC (1997) Meta-analysis of randomized control trials addressing brief interventions. J Gen Intern Med 12(5):274–283PubMedCrossRef

105.

Yamashita Y, Kawamura T, Rumi Fujikawa R et al (2006) Regression of both pituitary and ovarian cysts after administration of Thyroid hormone in a case of primary hypothyroidism. Intern Med 40(8):751–755CrossRef

Title: Schizophrenia and Stein–Leventhal syndrome: comorbidity features
Author: Naira R. Matevosyan
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-011-1963-1

At a glance: The STEP trials

Springer Medicine

Schizophrenia and Stein–Leventhal syndrome: comorbidity features

Abstract

Objective

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

The assessment of voluntary pelvic floor muscle contraction by three-dimensional transperineal ultrasonography

Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum

Prospective study of maternal and neonatal outcome in great-grand multiparous women (≥10 births) and in aged-matched women with lesser parity

Cervical cytology of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H): histological results and recurrence after a loop electrosurgical excision procedure

Radiotherapy for Japanese elderly patients with cervical cancer: preliminary survival outcomes and evaluation of treatment-related toxicity

Timing of intrauterine insemination: an attempt to unravel the enigma